دورية أكاديمية
Cascade screening in HBOC and Lynch syndrome: guidelines and procedures in a UK centre.
| العنوان: | Cascade screening in HBOC and Lynch syndrome: guidelines and procedures in a UK centre. |
|---|---|
| المؤلفون: | Evans DG; Manchester Centre for Genomic Medicine and North-West Genomics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK. gareth.evans@mft.nhs.uk.; Division of Evolution Infection and Genomic Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, School of Biological Sciences, University of Manchester, Manchester, M13 9PL, UK. gareth.evans@mft.nhs.uk., Green K; Manchester Centre for Genomic Medicine and North-West Genomics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK., Burghel GJ; Manchester Centre for Genomic Medicine and North-West Genomics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK., Forde C; Manchester Centre for Genomic Medicine and North-West Genomics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK., Lalloo F; Manchester Centre for Genomic Medicine and North-West Genomics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK., Schlecht H; Manchester Centre for Genomic Medicine and North-West Genomics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK., Woodward ER; Manchester Centre for Genomic Medicine and North-West Genomics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK.; Division of Evolution Infection and Genomic Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, School of Biological Sciences, University of Manchester, Manchester, M13 9PL, UK. |
| المصدر: | Familial cancer [Fam Cancer] 2024 Jun; Vol. 23 (2), pp. 187-195. Date of Electronic Publication: 2024 Mar 13. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: Netherlands NLM ID: 100898211 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7292 (Electronic) Linking ISSN: 13899600 NLM ISO Abbreviation: Fam Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Dordrecht : Springer Original Publication: Dordrecht ; Boston : Kluwer Academic Publishers, c2001- |
| مواضيع طبية MeSH: | Colorectal Neoplasms, Hereditary Nonpolyposis*/genetics , Colorectal Neoplasms, Hereditary Nonpolyposis*/diagnosis , Genetic Testing*/methods , Genetic Testing*/standards , Hereditary Breast and Ovarian Cancer Syndrome*/genetics , Hereditary Breast and Ovarian Cancer Syndrome*/diagnosis , Practice Guidelines as Topic* , Genetic Predisposition to Disease*, Humans ; Female ; United Kingdom ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; MutS Homolog 2 Protein/genetics ; Early Detection of Cancer/methods ; MutL Protein Homolog 1/genetics ; Germ-Line Mutation ; DNA-Binding Proteins/genetics ; Mismatch Repair Endonuclease PMS2/genetics ; Male ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/diagnosis |
| مستخلص: | In the 33 years since the first diagnostic cancer predisposition gene (CPG) tests in the Manchester Centre for Genomic Medicine, there has been substantial changes in the identification of index cases and cascade testing for at-risk family members. National guidelines in England and Wales are usually determined from the National Institute of healthcare Evidence and these have impacted on the thresholds for testing BRCA1/2 in Hereditary Breast Ovarian Cancer (HBOC) and in determining that all cases of colorectal and endometrial cancer should undergo screening for Lynch syndrome. Gaps for testing other CPGs relevant to HBOC have been filled by the UK Cancer Genetics Group and CanGene-CanVar project (web ref. https://www.cangene-canvaruk.org/ ). We present time trends (1990-2020) of identification of index cases with germline CPG variants and numbers of subsequent cascade tests, for BRCA1, BRCA2, and the Lynch genes (MLH1, MSH2, MSH6 and PMS2). For BRCA1/2 there was a definite increase in the proportion of index cases with ovarian cancer only and pre-symptomatic index tests both doubling from 16 to 32% and 3.2 to > 8% respectively. A mean of 1.73-1.74 additional family tests were generated for each BRCA1/2 index case within 2 years. Overall close to one positive cascade test was generated per index case resulting in > 1000 risk reducing surgery operations. In Lynch syndrome slightly more cascade tests were performed in the first two years potentially reflecting the increased actionability in males with 42.2% of pre-symptomatic tests in males compared to 25.8% in BRCA1/2 (p < 0.0001). (© 2024. The Author(s).) |
| References: | Santibáñez-Koref MF, Birch JM, Hartley AL, Jones PH, Craft AW, Eden T, Crowther D, Kelsey AM, Harris M (1991) p53 germline mutations in Li-Fraumeni syndrome. Lancet 338(8781):1490–1491. https://doi.org/10.1016/0140-6736(91)92303-j. (PMID: 10.1016/0140-6736(91)92303-j1683921) Eccles DM, Evans DG, Mackay J (2000) Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). J Med Genet 37(3):203–209. https://doi.org/10.1136/jmg.37.3.203. (PMID: 10.1136/jmg.37.3.203106990571734545) Hodgson SV, Bishop DT, Dunlop MG, Evans DG, Northover JM (1995) Suggested screening guidelines for familial colorectal cancer. J Med Screen 2(1):45–51. https://doi.org/10.1177/096914139500200112. (PMID: 10.1177/0969141395002001127497146) McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, Easton D, Emery J, Gray J, Halpin J, Hopwood P, McKay J, Sheppard C, Sibbering M, Watson W, Wailoo A, Hutchinson A (2004 updated 2006 and 2013) Clinical Guidelines and Evidence Review for The Classification and Care of Women at Risk of Familial Breast Cancer, London: National Collaborating Centre for Primary Care/University of Sheffield. NICE guideline CG164. https://www.nice.org.uk/Guidance/CG164 . Accessed 2 Aug 2023. https://www.england.nhs.uk/wp-content/uploads/2018/08/Rare-and-inherited-disease-eligibility-criteria-version-5.2.pdf . Accessed 2 Aug 2023. Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, Mitchell CL, Badea D, Moon S, Hogg M, Hadjiyiannakis D, Clancy T, Schlecht H, Woodward ER, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Lalloo FI, Harkness EF, Evans DGR (2020) Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. Eur J Hum Genet 28(11):1541–1547. https://doi.org/10.1038/s41431-020-0692-y. (PMID: 10.1038/s41431-020-0692-y326515527575602) Evans DG et al (2023) Population based germline testing of BRCA1, BRCA2 and PALB2 in breast cancer patients in the UK: evidence to support extended testing and definition of groups who may not require testing. Genet Med Open. https://doi.org/10.1016/j.gimo.2023.100849. (PMID: 10.1016/j.gimo.2023.100849) Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M, Consensus meeting attendees, Lalloo F (2023) UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2. J Med Genet 60(5):417–429. https://doi.org/10.1136/jmg-2022-108898. (PMID: 10.1136/jmg-2022-10889836411032) Woodward ER, van Veen EM, Forde C, Harkness EF, Byers HJ, Ellingford JM, Burghel GJ, Schlech H, Bowers NL, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ, Gareth Evans D (2021) Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Genet Med 23(10):1969–1976. https://doi.org/10.1038/s41436-021-01234-6. (PMID: 10.1038/s41436-021-01234-6341130038486655) Carver T, Hartley S, Lee A, Cunningham AP, Archer S, Babb de Villiers C, Roberts J, Ruston R, Walter FM, Tischkowitz M, Easton DF, Antoniou AC (2021) CanRisk tool—a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants. Cancer Epidemiol Biomarkers Prev 30(3):469–473. https://doi.org/10.1158/1055-9965.EPI-20-1319. (PMID: 10.1158/1055-9965.EPI-20-131933335023) Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425. (PMID: 10.1007/BF020536992022152) Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456. (PMID: 10.1016/S0016-5085(99)70510-X10348829) Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM et al (1997) A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758–1762. (PMID: 10.1093/jnci/89.23.17589392616) Evans DG, Lalloo F, Ryan NA, Bowers N, Green K, Woodward ER, Clancy T, Bolton J, McVey RJ, Wallace AJ, Newton K, Hill J, McMahon R, Crosbie EJ (2022) Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers. J Med Genet 59(4):328–334. https://doi.org/10.1136/jmedgenet-2020-107542. (PMID: 10.1136/jmedgenet-2020-10754233452216) https://www.nice.org.uk/guidance/dg27/chapter/1-Recommendations . Accessed 2 Aug 2023. https://www.nice.org.uk/guidance/dg42/chapter/1-Recommendations . Accessed 2 Aug 2023. Ryan NAJ, McMahon R, Tobi S, Snowsill T, Esquibel S, Wallace AJ, Bunstone S, Bowers N, Mosneag IE, Kitson SJ, O’Flynn H, Ramchander NC, Sivalingam VN, Frayling IM, Bolton J, McVey RJ, Evans DG, Crosbie EJ (2020) The proportion of endometrial tumours associated with Lynch syndrome (PETALS): a prospective cross-sectional study. PLoS Med 17(9):e1003263. https://doi.org/10.1371/journal.pmed.1003263. (PMID: 10.1371/journal.pmed.1003263329414697497985) Maddock IR, Moran A, Maher ER, Teare MD, Norman A, Payne SJ et al (1996) A genetic register for von Hippel-Lindau disease. J Med Genet 33:120–127. (PMID: 10.1136/jmg.33.2.12089299481051837) Evans DG, Maher ER, Macleod R, Davies DR, Craufurd D (1997) Uptake of genetic testing for cancer predisposition. J Med Genet 34:746–748. (PMID: 10.1136/jmg.34.9.74693217611051059) Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS et al (2008) IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:1282–1291. (PMID: 10.1002/humu.20880189514463075918) Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17:405–423. (PMID: 10.1038/gim.2015.30257418684544753) Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167. (PMID: 10.1038/ng195917200668) Rebbeck TR, Burns-White K, Chan AT, Emmons K, Freedman M, Hunter DJ et al (2018) Precision prevention and early detection of cancer: fundamental principles. Cancer Discov 8:803–811. (PMID: 10.1158/2159-8290.CD-17-141529907587) Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244–250. (PMID: 10.1200/JCO.2014.56.272825366685) Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med 372:2509–2520. (PMID: 10.1056/NEJMoa150059626028255) Morgan RD, Burghel GJ, Flaum N, Bulman M, Clamp AR, Hasan J et al (2019) Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. J Med Genet 56:301–307. (PMID: 10.1136/jmedgenet-2018-10579230683677) Woodward ER, Green K, Burghel GJ, Bulman M, Clancy T, Lalloo F, Schlecht H, Wallace AJ, Evans DG (2022) 30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes. Eur J Hum Genet 30(4):413–419. https://doi.org/10.1038/s41431-021-01011. (PMID: 10.1038/s41431-021-0101134866136) Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C et al (2021) Breast cancer risk genes: association analysis in more than 113,000 women. New Engl J Med 384:428–439. (PMID: 10.1056/NEJMoa1913948) Forde C, Brunstrom K, Woodward E, Bowers N, Pereira M, Wallace AJ, Lalloo F, Harkness EF, Evans DG (2020) Uptake of pre-symptomatic testing for BRCA1 and BRCA2 is age, gender, offspring and time-dependent. J Med Genet. https://doi.org/10.1136/jmedgenet-2019-106544. (PMID: 10.1136/jmedgenet-2019-10654432354797) Barrow P, Green K, Clancy T, Lalloo F, Hill J, Evans DG (2015) Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey. Clin Genet 87(6):517–524. https://doi.org/10.1111/cge.12559. (PMID: 10.1111/cge.1255925652327) |
| معلومات مُعتمدة: | IS-BRC-1215-200074 Manchester Biomedical Research Centre |
| فهرسة مساهمة: | Keywords: BRCA1/2; Cancer predisposition gene (CPG); Genetic testing; Lynch syndrome |
| المشرفين على المادة: | 0 (BRCA2 protein, human) EC 3.6.1.3 (MSH2 protein, human) 0 (BRCA1 Protein) 0 (BRCA2 Protein) EC 3.6.1.3 (MutS Homolog 2 Protein) 0 (BRCA1 protein, human) 0 (G-T mismatch-binding protein) EC 3.6.1.3 (MutL Protein Homolog 1) 0 (MLH1 protein, human) EC 3.6.1.- (PMS2 protein, human) 0 (DNA-Binding Proteins) EC 3.6.1.3 (Mismatch Repair Endonuclease PMS2) |
| تواريخ الأحداث: | Date Created: 20240313 Date Completed: 20240605 Latest Revision: 20240709 |
| رمز التحديث: | 20240710 |
| مُعرف محوري في PubMed: | PMC11153258 |
| DOI: | 10.1007/s10689-024-00360-9 |
| PMID: | 38478259 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1573-7292 |
|---|---|
| DOI: | 10.1007/s10689-024-00360-9 |